Glenn David is recorded as CFO at Zoetis Inc. (ZTS). Zoetis Inc. reported in an 8-K filed February 7, 2023 that Glenn David was terminated as Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, effective February 5, 2023. Zoetis Inc. reported in an 8-K filed October 25, 2022 that Glenn David was appointed Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, effective November 1, 2022. The proxy statement of Zoetis Inc. reports total compensation of $3,672,350 for Glenn David in fiscal 2019, including a base salary of $690,000. Disclosed compensation is on record for 3 fiscal years. Glenn David has spoken on 4 earnings calls across 1 company, most recently for Zoetis Inc. on May 6, 2021. Zoetis Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Zoetis Inc. includes Juan Ramón Alaix (CEO), James (Jay) Saccaro (CFO), James Saccaro (CFO and COO) and 7 others.
“On February 5, 2023, Zoetis terminated Glenn David, Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc. (the "Company"), for violating company policy by engaging in a consensual personal relationship and failing to disclose it to the Company.”
Zoetis Inc. Form 8-K, filed February 7, 2023
· Read the filing
“Zoetis Inc. (the "Company") appointed Glenn David as the Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, effective November 1, 2022.”
Zoetis Inc. Form 8-K, filed October 25, 2022
· Read the filing
Glenn David on recent calls
“As Kristin mentioned, we had a very strong start to the year, delivering substantial growth on a global basis and across species and therapeutic areas.”
“We had another exceptional year with revenue of $6.7 billion and adjusted net income of $1.8 billion, both exceeding the high end of our November full-year guidance range.”
“I hope you and your families are remaining safe and healthy during these difficult times, and I thank you for joining us today. We delivered another solid quarter with significant growth in both our companion animal and livestock portfolios.”
“I hope everyone is safe, healthy, and adapting to what is certainly an unprecedented time for all of us. Today, we'll provide additional commentary on our Q2 financial results, provide an update on our liquidity position, and review our improved full year 2020 guidance.”
